H.C. Wainwright & Co.

InMed Pharmaceuticals Secures $6M Via Private Placement

Zynerba Pharmaceuticals R&D Expenses For Q3 Reach $5M, Here Are The Details

HAVN Life Closes First Tranche Of July Financing By ABO, Details On Amendments And Debt Shares Issuance

Zynerba Pharmaceuticals R&D Expenses For Q3 Reach $5M, Here Are The Details

HAVN Life Closes First Tranche Of July Financing By ABO, Details On Amendments And Debt Shares Issuance

InMed Pharmaceuticals Announces $5 Million Registered Direct And Private Placement Offerings

Advertising, Acquisition And Potential Subscription Model Point To $6PT For Super League Gaming

InMed Pharmaceuticals Announces $5 Million Registered Direct And Private Placement Offerings

|

Advertising, Acquisition And Potential Subscription Model Point To $6PT For Super League Gaming

|

'Pleasantly Surprised' Acadia Analysts See Blockbuster Potential For Pimavanserin In Dementia Psychosis

|

Alzheon's IPO: What You Need To Know

|

H.C. Wainwright & Co. Recent News

Analyst: Biofuel Company Gevo Could More Than Quadruple Revenue By 2025

|

What You Should Know About The Drug Approval Valeant Could Receive This Week

|

Do Any Signs Of Life Remain In OnceMed's Demcizumab Development?

|

Where Does Anthera Go From Here?

|

H.C. Wainwright Is Bullish On Cara Therapeutics Shares

|

Galectin Shares Downgraded As NASH-FX Failure Likely Degrades The Prognosis For NASH-CX

|

H.C. Wainwright Initiates Mirna At Buy, Sees 135% Upside

|

H.C. Wainwright Sees Nearly 200% Upside In Vascular Biogenics

|

H.C. Wainwright Downgrades United Therapeutics To Neutral

|

Cardiome Is A 'Rising Global Spec Pharma Play With Growth Potential'

|

H.C. Wainwright Initiates Radius Health At Buy, $55 Target

|

HC Wainwright Upgrades Caladrius Biosciences To Buy, Sets $1.25 Price Target

|

H.C. Wainwright Triples Celator Valuation, Says Latest Trial Win Is Rare

|

H.C. Wainwright Still Buying Amarin, Sees DMC Decision By Summer

|

Biocept Could Double On Liquid Biopsy Leadership: H.C. Wainwright

|

What's Happening At The ASCO Conference?

|

H.C. Wainwright Initiates Coverage On Celladon, Cites Impressive Trial Results For Heart Failure Therapy

|

H.C. Wainwright & Co. Retains Positive Outlook On OXiGENE

|

UPDATE: H.C. Wainwright & Co. Initiates Coverage On Oncothyreon On Significant Upside

|

UPDATE: H.C. Wainwright & Co. Initiates Coverage On Finjan Holdings, Inc. On Multiple Positive Factors

|

UPDATE: H.C. Wainwright & Co. Initiates Coverage On PolyMet Mining Corp. (USA) On Large-Scale Minnesota Project

|

Threshold Pharmaceuticals, Inc. Shares Jump Amid H.C. Wainwright Initiation

|

UPDATE: H.C. Wainwright & Co. Initiates Coverage On MELA Sciences On Commercialization Strategy Change

|